In the multivariate logistic regression model, SGLT2 inhibitor use (adjusted odds ratio [aOR]: 4.255; 95% confidence interval [CI]: 1.415–12.796; p = 0.010), improvement in general health perception (aOR: 1.076; 95% CI: 1.004–1.154; p = 0.037), and reduction in anxiety scores (ΔBAI) (aOR: 0.803; 95% CI: 0.649–0.993; p = 0.043) were identified as independent predictors of sleep quality improvement (Table 5). The gene discussed is SLC5A2; the disease is Anxiety.